v3.26.1
Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Disaggregation of Revenue [Line Items]        
Total revenue $ 2,736.0 $ 2,645.5 $ 5,213.8 $ 5,076.5
Total revenues from anti-CD20 therapeutic programs 2,736.0 2,645.5 5,213.8 5,076.5
Genentech        
Disaggregation of Revenue [Line Items]        
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA 125.7 107.7 220.4 191.4
Other revenues from anti-CD20 therapeutic programs 6.4 5.8 13.6 11.5
Royalty Attributed To OCREVUS        
Disaggregation of Revenue [Line Items]        
Total revenue 381.4 353.8 698.6 642.6
Total revenues from anti-CD20 therapeutic programs 381.4 353.8 698.6 642.6
Revenue from anti-CD20 therapeutic programs        
Disaggregation of Revenue [Line Items]        
Total revenue 513.5 467.3 932.6 845.5
Total revenues from anti-CD20 therapeutic programs $ 513.5 $ 467.3 $ 932.6 $ 845.5